Fresenius 

0
988
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 4Expected
Q1 2026
Q2 2026
Q3 2026
0.73
0.78
0.83
0.88
Expected EPS
0.781819703824064
Actual EPS
0.7259891235839999

Financials

5.53%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
22.87BRevenue
1.26BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FREN.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
DaVita
DVA
Mkt Cap11.79B
DaVita Inc. provides kidney dialysis services, directly competing with Fresenius's dialysis services.
Baxter International
BAX
Mkt Cap11.9B
Baxter International Inc. offers dialysis products and services, competing in the same healthcare segment as Fresenius.
Medtronic
MDT
Mkt Cap123.49B
Medtronic plc manufactures and sells device-based medical therapies, including those that compete with Fresenius's medical devices.
Boston Scientific
BSX
Mkt Cap60.84B
Boston Scientific Corporation develops, manufactures, and markets medical devices that are in direct competition with some of Fresenius's product offerings.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson operates in the healthcare sector, offering products and services that compete across several of Fresenius's business lines.
Abbott Laboratories
ABT
Mkt Cap183.77B
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products that compete with Fresenius.
Stryker
SYK
Mkt Cap111.95B
Stryker Corporation specializes in medical devices, competing with Fresenius in the medical equipment and services market.
Zimmer Biomet
ZBH
Mkt Cap18.03B
Zimmer Biomet Holdings, Inc. manufactures and markets orthopedic reconstructive products, competing with Fresenius's medical devices segment.
Becton Dickinson
BDX
Mkt Cap53.9B
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products, competing with Fresenius.

About

Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
Show More
CEO
Michael Sen
Employees
178486
Country
Germany
ISIN
DE000A2TSV53

Listings

0 Comments

Share your thoughts

FAQs

What is Fresenius stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Fresenius stocks are traded under the ticker FREN.MU.
When is the next Fresenius earnings date?▼
Fresenius is going to release the next earnings report on February 24, 2027.
What were Fresenius earnings last quarter?▼
FREN.MU earnings for the last quarter are 0.73 EUR per share, whereas the estimation was 0.78 EUR resulting in a -7.14% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Fresenius revenue for the last year?▼
Fresenius revenue for the last year amounts to 22.87B EUR.
What is Fresenius net income for the last year?▼
FREN.MU net income for the last year is 1.26B EUR.
How many employees does Fresenius have?▼
As of November 7, 2026, the company has 178,486 employees.
In which sector is Fresenius located?▼
Fresenius operates in the Health & Wellness sector.
When did Fresenius complete a stock split?▼
Fresenius has not had any recent stock splits.
Where is Fresenius headquartered?▼
Fresenius is headquartered in Bad Homburg vor der Höhe, Germany.